Loading
Ribociclib · Regulatory label update
U.S. Food and Drug Administration · July 1, 2026
An action by a regulator. Authoritative on labelling and availability.
This is an FDA supplemental approval action for ribociclib (Kisqali) on an efficacy basis, dated 1 July 2026. The record itself does not contain clinical trial data, efficacy results, comparator data, or safety information. The approval signals regulatory authorization for an indication or population expansion, but clinical evidence supporting the decision is not presented in this document.
Regulatory label update. Intervention: Ribociclib (Kisqali) tablet, oral, 200 mg base (as succinate salt).
This is an FDA supplemental approval action for ribociclib (Kisqali) on an efficacy basis, dated 1 July 2026. The record itself does not contain clinical trial data, efficacy results, comparator data, or safety information. The approval signals regulatory authorization for an indication or population expansion, but clinical evidence supporting the decision is not presented in this document.
Safety profile, adverse event data, and contraindications are not reported here.
Clinicians should consult the full prescribing information and FDA approval summary to understand the approved indication, patient population, dosing, and supporting clinical evidence. This regulatory notice alone does not provide sufficient clinical detail to inform treatment decisions.
FDA supplemental approval for efficacy expansion of ribociclib; regulatory action does not report trial outcomes and does not constitute clinical evidence of practice-changing benefit.
As stated by the source record.
Clinicians should consult the full prescribing information and FDA approval summary to understand the approved indication, patient population, dosing, and supporting clinical evidence. This regulatory notice alone does not provide sufficient clinical detail to inform treatment decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.
Drugs@FDA record for application NDA209092. This is a regulatory action record, not a clinical study. Brand name: KISQALI. Active ingredient: RIBOCICLIB. Sponsor: NOVARTIS. Submission type: SUPPL (supplement). Submission class: Efficacy. Approval status date: 2026-07-01. Products: KISQALI, TABLET, ORAL, RIBOCICLIB SUCCINATE EQ 200MG BASE.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.